Autobio Diagnostics Co., Ltd.
SSE:603658.SS
37.46 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 4,471.203 | 4,443.656 | 4,441.627 | 3,765.917 | 2,978.132 | 2,679.436 | 1,929.676 | 1,400.142 | 980.223 | 716.489 | 563.296 | 409.365 | 318.146 | 211.845 |
| Cost of Revenue
| 1,546.574 | 1,552.245 | 1,783.657 | 1,525.628 | 1,198.723 | 895.744 | 648.814 | 455.237 | 274.616 | 195.118 | 151.704 | 120.408 | 91.833 | 59.897 |
| Gross Profit
| 2,924.629 | 2,891.411 | 2,657.97 | 2,240.289 | 1,779.408 | 1,783.692 | 1,280.862 | 944.905 | 705.607 | 521.37 | 411.591 | 288.956 | 226.314 | 151.947 |
| Gross Profit Ratio
| 0.654 | 0.651 | 0.598 | 0.595 | 0.597 | 0.666 | 0.664 | 0.675 | 0.72 | 0.728 | 0.731 | 0.706 | 0.711 | 0.717 |
| Reseach & Development Expenses
| 731.933 | 656.13 | 568.476 | 480.959 | 342.798 | 311.906 | 212.732 | 142.683 | 102.059 | 61.171 | 58.111 | 47.664 | 33.856 | 0 |
| General & Administrative Expenses
| 49.497 | 39.992 | 33.415 | 34.688 | 41.832 | 44.229 | 33.238 | 25.603 | 19.332 | 10.488 | 11.729 | 11.17 | 62.532 | 43.845 |
| Selling & Marketing Expenses
| 317.979 | 331.505 | 717.836 | 629.697 | 464.671 | 441.018 | 316.304 | 234.783 | 146.895 | 108.799 | 82.726 | 69.48 | 53.082 | 36.481 |
| SG&A
| 367.477 | 896.035 | 751.25 | 664.385 | 506.503 | 485.246 | 349.542 | 260.387 | 166.227 | 119.287 | 94.456 | 80.65 | 115.614 | 80.326 |
| Other Expenses
| 579.73 | -31.968 | 103.986 | 97.18 | 71.095 | 66.438 | 0.615 | 8.853 | 14.126 | 12.967 | 10.105 | 10.413 | 10.551 | 3.681 |
| Operating Expenses
| 1,679.14 | 1,518.195 | 1,423.712 | 1,242.524 | 920.396 | 863.59 | 626.657 | 450.322 | 313.748 | 210.843 | 178.029 | 152.184 | 119.791 | 83.022 |
| Operating Income
| 1,245.489 | 1,365.748 | 1,296.382 | 1,076.152 | 856.366 | 894.24 | 653.94 | 506.177 | 394.426 | 312.031 | 232.951 | 134.499 | 105.672 | 68.122 |
| Operating Income Ratio
| 0.279 | 0.307 | 0.292 | 0.286 | 0.288 | 0.334 | 0.339 | 0.362 | 0.402 | 0.435 | 0.414 | 0.329 | 0.332 | 0.322 |
| Total Other Income Expenses Net
| 43.568 | -3.204 | -2.667 | -10.603 | -11.834 | -8.498 | 0.615 | 8.853 | 13.35 | 12.788 | 8.994 | 10.008 | 10.551 | 3.681 |
| Income Before Tax
| 1,289.056 | 1,362.544 | 1,293.715 | 1,065.549 | 844.533 | 885.742 | 654.556 | 515.03 | 407.785 | 324.819 | 241.944 | 144.507 | 116.223 | 71.804 |
| Income Before Tax Ratio
| 0.288 | 0.307 | 0.291 | 0.283 | 0.284 | 0.331 | 0.339 | 0.368 | 0.416 | 0.453 | 0.43 | 0.353 | 0.365 | 0.339 |
| Income Tax Expense
| 89.823 | 138.413 | 105.033 | 85.693 | 87.442 | 98.842 | 79.547 | 65.343 | 58.027 | 46.792 | 33.723 | 20.432 | 20.101 | 10.085 |
| Net Income
| 1,194.452 | 1,217.439 | 1,167.437 | 973.663 | 747.794 | 774.164 | 562.571 | 446.564 | 349.758 | 278.027 | 208.221 | 124.075 | 96.122 | 61.154 |
| Net Income Ratio
| 0.267 | 0.274 | 0.263 | 0.259 | 0.251 | 0.289 | 0.292 | 0.319 | 0.357 | 0.388 | 0.37 | 0.303 | 0.302 | 0.289 |
| EPS
| 2.07 | 2.1 | 2 | 1.66 | 1.34 | 1.42 | 1.03 | 0.82 | 0.68 | 0.57 | 0.42 | 0.25 | 0.19 | 2.35 |
| EPS Diluted
| 2.07 | 2.1 | 2 | 1.66 | 1.34 | 1.42 | 1.03 | 0.82 | 0.68 | 0.57 | 0.42 | 0.25 | 0.19 | 2.35 |
| EBITDA
| 1,789.123 | 1,872.756 | 1,777.221 | 1,498.922 | 1,193.013 | 1,130.874 | 832.07 | 640.852 | 487.74 | 375.135 | 263.369 | 154.034 | 117.679 | 75.326 |
| EBITDA Ratio
| 0.4 | 0.421 | 0.4 | 0.398 | 0.401 | 0.422 | 0.431 | 0.458 | 0.498 | 0.524 | 0.468 | 0.376 | 0.37 | 0.356 |